ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1029

Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry

Allison Guttmann1, Brendan Denvir1, Jill Buyon2, Martin Aringer3, H. Michael Belmont2, Sara Sahl4, Jane Salmon5, Anca Askanase6, Joan Bathon7, Laura Geraldino8, Yousaf Ali9, Ellen Ginzler10, Chaim Putterman11, Caroline Gordon12, Charles Helmick13, Hilary Parton14 and Peter Izmirly1, 1New York University School of Medicine, New York, NY, 2NYU School of Medicine, New York, NY, 3Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, 4UCLA-Harbor, Los Angeles, CA, 5Hospital for Special Surgery, New York, NY, 6Columbia University Medical Center, New York, NY, 7Columbia University, New York, NY, 8New York Presbyterian Hospital - Columbia Campus, New York, NY, 9Icahn School of Medicine at Mount Sinai, New York, NY, 10SUNY Downstate Health Sciences University, Brooklyn, NY, 11Albert Einstein College of Medicine, Bronx, NY, 12Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 13Centers for Disease Control and Prevention, Atlanta, GA, 14New York City Department of Health and Mental Hygiene, Long Island City, NY

Meeting: ACR Convergence 2021

Keywords: classification criteria, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: The Manhattan Lupus Surveillance Program (MLSP) is a multi-racial/ethnic population-based registry with the primary goal to determine the prevalence and incidence of Systemic Lupus Erythematosus (SLE). In this study, we compare the three most commonly used classification criteria for SLE (1997 revised ACR, Systemic Lupus International Collaborating Clinics (SLICC) and the recent EULAR/ACR classification criteria) to identify cases that fulfilled only one of the classification criteria and explore each criteria set’s unique cases. In addition, we used the EULAR/ACR criteria to determine the incidence and prevalence of SLE in Manhattan.

Methods: MLSP cases were identified from Manhattan-based hospitals and rheumatologists, and state population databases. For this analysis, SLE cases were defined as fulfilling 1) the 1997 ACR classification criteria, 2) the SLICC criteria or 3) EULAR/ACR classification criteria. We quantified the number of cases that uniquely associated with each classification criteria and the number that fulfilled all three classifications. Prevalence (2007) and incidence rates (2007-2009) using the EULAR/ACR classification criteria and associated 95% confidence intervals (CI) were calculated using denominators obtained from the US Census data (revised 2000-2009 intercensal population files) for Manhattan.

Results: Overall 1,568 cases fulfilled at least one of the three classification criteria. Of those, 1008 (64.3%) cases fulfilled all three classification criteria, 166 (10.5%) fulfilled only the SLICC criteria, 50 (3.2%) fulfilled only the 1997 ACR criteria and 36 (2.3%) fulfilled the EULAR/ACR criteria with the remaining cases fulfilling a combination of two classification criteria. Cases that only met one of the classification criteria, and the reasons why they did not meet the other two classification criteria with example cases, are detailed in Tables 1-3. Based on the EULAR/ACR classification criteria, the age-adjusted overall prevalence and incidence rates of SLE in Manhattan were 59.8 (n=1,029, 95%CI:56.1- 63.6) and 4.9 (n=245, 95%CI 4.3-5.5) per 100,000 population. Prevalence was 9 times higher and incidence was 6.9 times higher among females compared to males. The age-adjusted prevalence per 100,000 was highest among non-Hispanic Black females (198.9), followed by Hispanic females (133.1), non-Hispanic Asian/Pacific Islander females (97.7) and non-Hispanic White females (59.8). Age-adjusted incidence rates per 100,000 were highest in non-Hispanic Black females (15.8), followed by Hispanic females (7.5), non-Hispanic Asian/Pacific Islander females (7.3) and non-Hispanic White females (6.3). Prevalence and incidence rates for males followed a similar pattern.

Conclusion: Applying the three commonly used classification systems to a multi-racial/ethnic population-based registry allowed for identifying unique cases of SLE who only fulfilled one classification system. The EULAR/ACR classification criteria revealed similar prevalence and incidence estimates and gender and racial/ethnic disparities to the previously published results from the MLSP using the 1997 revised ACR and SLICC classification criteria.

Table 1 – Explanations for patients meeting ACR criteria only

Table 2 – Explanations for patients meeting SLICC criteria only

Table 3 – Explanations for patients meeting EULAR/ACR criteria only


Disclosures: A. Guttmann, None; B. Denvir, None; J. Buyon, Bristol Myers Squibb, 1, GlaxoSmithKline, 2, Janssen, 2, Ventus, 2, Equillium, 2; M. Aringer, Boehringer Ingelheim, 1, 6, Roche, 1, 6; H. Belmont, Alexion, 6; S. Sahl, None; J. Salmon, UCB, 1, 5, BMS, 1, Aurinia, 1; A. Askanase, GSK, 2, 5, AstraZeneca, 1, 5, Amgen, 1, Aurinia, 2, Abbvie, 1, Pfizer, 5, Eli Lilly, 5, Idorsia, 5; J. Bathon, None; L. Geraldino, None; Y. Ali, None; E. Ginzler, None; C. Putterman, equllium, 2, 5, Progentec, 2, Kidneycure, 2; C. Gordon, Centre for Disease Control, 2, 6, Astra-Zeneca, 2, 6, MGP, 2, 6, Sanofi, 2, 6, UCB, 2, UCB, 5, 6; C. Helmick, None; H. Parton, None; P. Izmirly, Momenta/Janssen, 1.

To cite this abstract in AMA style:

Guttmann A, Denvir B, Buyon J, Aringer M, Belmont H, Sahl S, Salmon J, Askanase A, Bathon J, Geraldino L, Ali Y, Ginzler E, Putterman C, Gordon C, Helmick C, Parton H, Izmirly P. Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-the-eular-acr-classification-criteria-for-systemic-lupus-erythematosus-in-a-population-based-registry/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-the-eular-acr-classification-criteria-for-systemic-lupus-erythematosus-in-a-population-based-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences